IGM Biosciences Inc
Change company Symbol lookup
Select an option...
IGMS IGM Biosciences Inc
ICGL Image Chain Group Limited Inc
HUSIF Nicola Mining Inc
SO Southern Co
ERC Wells Fargo Multi-Sector Income Fund
ASG Liberty All-Star Growth
ARPO Aerpio Pharmaceuticals Inc
AMRQQ Alta Mesa Resources Inc
XAIR Beyond Air Inc
USA Liberty All-Star Equity
Go

Company profile

IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).

Closing Price
$22.72
Day's Change
1.20 (5.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
23.00
Day's Low
20.34
Volume
(Heavy Day)
Volume:
207,271

10-day average volume:
146,803
207,271

UPDATE: Wells Fargo snubbed by top candidates for CEO role: WSJ

9:49 am ET June 11, 2019 (MarketWatch)
Print

(END) Dow Jones Newswires

June 11, 2019 09:49 ET (13:49 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.